Does lurbinectedin lower blood pressure?
No, lurbinectedin does not lower blood pressure. Clinical data and prescribing information list hypotension as a rare adverse reaction, occurring in less than 1% of patients, rather than a common or intended effect.[1][2]
What side effects does lurbinectedin cause?
Lurbinectedin (brand name Zepzelca), approved for small cell lung cancer, commonly causes fatigue (up to 58%), nausea (44%), decreased appetite (39%), and myelosuppression like anemia (53%) and neutropenia (58%). Cardiovascular effects include hypertension (5%) more often than hypotension (<1%). Serious risks involve hepatotoxicity and rhabdomyolysis.[1][3]
How does lurbinectedin affect the cardiovascular system?
Trials like the phase 2 basket study (NCT02454972) reported hypertension in 5% of patients and hypotension in 1%, with no evidence of blood pressure reduction as a primary mechanism. The drug inhibits RNA polymerase II, disrupting tumor cell transcription, without direct vasodilatory or antihypertensive actions.[2][4]
Why might someone experience low blood pressure on lurbinectedin?
Hypotension cases link to dehydration from nausea/vomiting, sepsis from neutropenia, or concurrent medications, not the drug itself. Patients with baseline low blood pressure or on antihypertensives need monitoring; dose adjustments occur for grade 3-4 events.[1][3]
Compared to similar cancer drugs, what's unique?
Unlike platinum chemotherapies (e.g., cisplatin, which can cause hypertension via renal effects), lurbinectedin shows balanced hypertensive/hypotensive risks. Immunotherapies like atezolizumab pair with it without amplifying blood pressure drops.[3][5]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, FDA label 2020 (updated 2023).
[2]: Trigo et al., Lancet Oncology 2020;19:1050-1061. Phase 2 trial data.
[3]: FDA approval summary, Clinical Cancer Research 2021.
[4]: ClinicalTrials.gov NCT02454972 results.
[5]: IMpower133 trial, Horn et al., NEJM 2018.